Why This Marijuana Stock Crashed 18% in September

Image source Getty Images What happened Less than a year after reassuming the reins following the exit of embattled CEO Michael Babich Insys Therapeutics NASDAQ INSY 160 founder and principal investor John Kapoor has decided to leave the company to pursue